ACE inhibitors and the kidney. A risk-benefit assessment.

Navis, G; Faber, H J; de Zeeuw, D; de Jong, P E

Navis, G; Faber, H J; de Zeeuw, D; de Jong, P E.

Affiliation

Navis G; Groningen Institute for Drug Studies (GIDS), Department of Internal Medicine, University Hospital Groningen, The Netherlands.

Drug Saf ; 15(3): 200-11, 1996 Sep.

Article in En | MEDLINE | ID: mdl-8879974

Subject(s)

Angiotensin-Converting Enzyme Inhibitors/adverse effects; Hypertension/drug therapy; Kidney/drug effects; Angiotensin-Converting Enzyme Inhibitors/pharmacology; Angiotensin-Converting Enzyme Inhibitors/therapeutic use; Drug Interactions; Humans; Kidney Diseases/drug therapy; Renal Insufficiency/drug therapy; Risk Assessment

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Angiotensin-Converting Enzyme Inhibitors / Hypertension / Kidney Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Drug Saf Journal subject: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Year: 1996 Document type: Article Affiliation country: Netherlands Country of publication: New Zealand

Search on Google

Add to My VHL

XML

PubMed Links